M. Lomas

724 total citations
23 papers, 518 citations indexed

About

M. Lomas is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, M. Lomas has authored 23 papers receiving a total of 518 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 4 papers in Surgery. Recurrent topics in M. Lomas's work include Cancer Treatment and Pharmacology (11 papers), Colorectal Cancer Treatments and Studies (6 papers) and Lung Cancer Research Studies (5 papers). M. Lomas is often cited by papers focused on Cancer Treatment and Pharmacology (11 papers), Colorectal Cancer Treatments and Studies (6 papers) and Lung Cancer Research Studies (5 papers). M. Lomas collaborates with scholars based in Spain. M. Lomas's co-authors include Á. Artal, J.L. González-Larriba, Alfredo Carrato, I. Barneto, Catalina Vadell, Joaquín Montalar, Antonio Antón, Rafael Rosell, P. Lianes and Vicente Alberola and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Lung Cancer.

In The Last Decade

M. Lomas

23 papers receiving 499 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. Lomas Spain	7	419	364	94	52	42	23	518
Giuseppe De Cataldis Italy	8	529 1.3×	518 1.4×	77 0.8×	60 1.2×	49 1.2×	14	708
Wayne Saville United States	4	347 0.8×	323 0.9×	57 0.6×	54 1.0×	34 0.8×	8	446
Emiddio Barletta Italy	12	395 0.9×	336 0.9×	92 1.0×	82 1.6×	66 1.6×	28	584
G.P. Nicolella Italy	10	634 1.5×	622 1.7×	116 1.2×	60 1.2×	59 1.4×	21	818
A. Chemaissani Germany	9	464 1.1×	508 1.4×	124 1.3×	37 0.7×	72 1.7×	13	650
F. Bustin Belgium	6	336 0.8×	354 1.0×	122 1.3×	47 0.9×	19 0.5×	11	459
N. Botwood United Kingdom	10	337 0.8×	314 0.9×	122 1.3×	40 0.8×	90 2.1×	19	525
Jane Bromund United States	9	447 1.1×	467 1.3×	127 1.4×	85 1.6×	42 1.0×	17	609
D. Brisgand France	5	639 1.5×	666 1.8×	155 1.6×	79 1.5×	50 1.2×	8	840
Guoqiang Wang China	9	455 1.1×	227 0.6×	89 0.9×	88 1.7×	62 1.5×	24	561

Countries citing papers authored by M. Lomas

Since Specialization

Citations

This map shows the geographic impact of M. Lomas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Lomas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Lomas more than expected).

Fields of papers citing papers by M. Lomas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Lomas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Lomas. The network helps show where M. Lomas may publish in the future.

Co-authorship network of co-authors of M. Lomas

This figure shows the co-authorship network connecting the top 25 collaborators of M. Lomas. A scholar is included among the top collaborators of M. Lomas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Lomas. M. Lomas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sánchez‐Rovira, Pedro, Miguel Ángel Seguí, Antonio Llombart‐Cussac, et al.. (2013). Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response. Clinical & Translational Oncology. 15(10). 810–817. 9 indexed citations

Salvador, J., Joan Albanell, Agustín Barnadas, et al.. (2012). Pilot study on workload estimate in breast cancer, lung cancer and colorectal cancer in a Medical Oncology Service at Valme hospital. Clinical & Translational Oncology. 14(11). 820–826. 1 indexed citations

Sánchez‐Rovira, Pedro, Antonio Antón, Agustí Barnadas, et al.. (2012). Classical markers like ER and ki-67, but also survivin and pERK, could be involved in the pathological response to gemcitabine, adriamycin and paclitaxel (GAT) in locally advanced breast cancer patients: results from the GEICAM/2002-01 phase II study. Clinical & Translational Oncology. 14(6). 430–436. 10 indexed citations

Salvador, J., Joan Albanell, Agustín Barnadas, et al.. (2012). Functions and workload of medical oncologists in Spain. Clinical & Translational Oncology. 14(6). 423–429. 6 indexed citations

Antón, Antonio, Agustí Barnadas, Jesús Florián, et al.. (2011). Biweekly vinorelbine and tegafur/uracil in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: GEICAM 2000–02 phase II study. Clinical & Translational Oncology. 13(4). 281–286. 3 indexed citations

Herrero, Eduardo Ferrero, et al.. (2009). 4011 Management of breast cancer in the elderly. European Journal of Cancer Supplements. 7(2). 218–218. 1 indexed citations

Lomas, M., et al.. (2008). A multicentre phase II study to evaluate sequential docetaxel followed by capecitabine treatment in anthracycline-pretreated HER-2-negative patients with metastatic breast cancer. Clinical & Translational Oncology. 10(12). 817–825. 1 indexed citations

Feliú, Jaime, Guillermo Martı́n, Javier de Castro, et al.. (2006). Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology. 58(4). 527–531. 5 indexed citations

Feliú, Jaime, Miguel Cruz, M. Lomas, et al.. (2006). Fixed dose-rate infusion of gemcitabine in combination with cisplatin and UFT in advanced carcinoma of the pancreas. Cancer Chemotherapy and Pharmacology. 58(4). 419–426. 4 indexed citations

10.

Aparicio, Jorge, José L. García-Puche, M. Lomas, et al.. (2006). Prognostic factors for relapse in stage I seminoma managed by surveillance or adjuvant carboplatin: A multivariate analysis on 588 cases. Journal of Clinical Oncology. 24(18_suppl). 4552–4552. 3 indexed citations

11.

Bernabé, Reyes, et al.. (2005). Docetaxel followed by capecitabine as first-line chemotherapy in metastatic breast cancer patients: Preliminary results. Journal of Clinical Oncology. 23(16_suppl). 801–801. 1 indexed citations

12.

Sánchez‐Rovira, Pedro, A. Antón, M. Lomas, et al.. (2005). Biweekly gemcitabine, doxorubicin and paclitaxel (GAT) regimen as neoadjuvant chemotherapy (NC) in locally advanced breast cancer (LABC) patients: Final results from 2002–01 GEICAM study. Journal of Clinical Oncology. 23(16_suppl). 842–842. 2 indexed citations

13.

Feliú, Jaime, Carlos García Girón, Emilio Fonseca, et al.. (2004). Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer. British Journal of Cancer. 91(10). 1758–1762. 16 indexed citations

14.

Castro, Javier de, Carlos García Girón, E. Fonseca, et al.. (2004). A combination of oxaliplatin and UFT-l,-leucovorin as first line treatment in advanced colorectal cancer. An ONCOPAZ phase II study. Journal of Clinical Oncology. 22(14_suppl). 3726–3726. 1 indexed citations

15.

Puértolas, Teresa, et al.. (2004). Phase II study of vinorelbine (NVB) and UFT in patients with metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes. Journal of Clinical Oncology. 22(14_suppl). 751–751. 4 indexed citations

16.

Artal, Á., José Gómez‐Codina, J.L. González-Larriba, et al.. (2004). Prospective Randomized Phase III Trial of Etoposide/Cisplatin Versus High-Dose Epirubicin/Cisplatin in Small-Cell Lung Cancer. Clinical Lung Cancer. 6(3). 175–183. 24 indexed citations

17.

Virizuela, Juan Antonio, Jesús Florián, M. Lomas, et al.. (2003). Gemcitabine/Vinorelbine in Metastatic Breast Cancer Patients Previously Treated with Anthracyclines: Results of a Phase II Trial. Clinical Breast Cancer. 4(1). 46–50. 14 indexed citations

18.

Muro, Xavier García del, Pablo Maroto, A. Barnadas, et al.. (2003). 884 Long-term results following one course of adjuvant chemotherapy for high-risk stage I non-seminomatous germ cell tumors: the Spanish germ cell cancer group experience. European Journal of Cancer Supplements. 1(5). S266–S266. 1 indexed citations

19.

Cardenal, F., Á. Artal, M. Lomas, et al.. (1997). 27 Gemcitabine plus cisplatin versus etoposide plus cisplatin in advanced non-small cell lung cancer: A randomized trial by the Spanish lung cancer group. Lung Cancer. 18. 10–10. 3 indexed citations

20.

Barón, Manuel González, Enrique Espinosa, Jaime Feliú, et al.. (1997). The UFT/Leucovorin/Etoposide Regimen for the Treatment of Advanced Gastric Cancer. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact